BioNTech Archives - Page 20 of 20 - Medical Design Sourcing

Drug companies agree not to release COVID-19 vaccine until it’s ready

[Photo by Fusion Medical Animation on Unsplash]

Executives from nine different drug companies today announced a pledge to ensure safety with a potential COVID-19 vaccine.

The CEOs of AstraZeneca (NYSE:AZN), BioNTech (NSDQ:BNTX), GlaxoSmithKline (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Moderna (NSDQ:MRNA), Novavax (NSDQ:NVAX), Pfizer (NYSE:PFE) and Sanofi (NYSE:SNY), all of whom are developing vaccine candidates, all signed the pledge, which vows to “uphold the integrity of the scientific process” as they pursue regulatory approvals of the first vaccines for the novel coronavirus.

Get the full story at our sister site, MassDevice.

Drug companies agree not to release COVID-19 vaccine until it’s ready

[Photo by Fusion Medical Animation on Unsplash]

Executives from nine different drug companies today announced a pledge to ensure safety with a potential COVID-19 vaccine.

The CEOs of AstraZeneca (NYSE:AZN), BioNTech (NSDQ:BNTX), GlaxoSmithKline (NYSE:GSK), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Moderna (NSDQ:MRNA), Novavax (NSDQ:NVAX), Pfizer (NYSE:PFE) and Sanofi (NYSE:SNY), all of whom are developing vaccine candidates, all signed the pledge, which vows to “uphold the integrity of the scientific process” as they pursue regulatory approvals of the first vaccines for the novel coronavirus.

“FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US,” the pledge states. “FDA’s guidance and criteria are based on the scientific and medical principles necessary to clearly dem…

Oxford researchers report positive early trial results for COVID-19 vaccine candidate

[Image from Unsplash]

Researchers at Oxford University say early-stage results from a Phase I/II clinical trial of a SARS-CoV-2 vaccine candidate display safety and strong immune responses.

Results, published in The Lancet, revealed that the vaccine is safe, causes few side effects and induces strong immune responses in both parts of the immune system in the fight against COVID-19, which is caused by SARS-CoV-2.

A T cell response (a cellular immune response) was provoked within 14 days of vaccination and an antibody response within 28 days. Researchers say that an ideal SARS-CoV-2 vaccine should be effective after one or two vaccinations, confer protection for a minimum of 6 months and reduce onward transmission of the virus to contacts.

“The immune system has two ways of finding and attacking pathogens — antibody and T cell responses,” lead author and Oxford professor Andrew Pollard sa…

Pfizer to outsource more production as it prepares for COVID-19 vaccine

Pfizer is turning to its 200-strong network of outside contractors to make more of its existing medicines as it prepares for a potential COVID-19 vaccine., according to media reports.

The New York–based pharmaceutical giant said May 5 that it will invest at-risk to produce millions of doses of a coronavirus vaccine in 2020, boosting production to hundreds of millions of doses in 2021. Pfizer sites in Massachusetts, Michigan, Missouri and Puurs, Belgium will serve as vaccine manufacturing centers — with more sites expected to be added to the list.

BioNTech — Pfizers’s partner in developing a COVID-19 vaccine — plans to ramp up production sites in Mainz and Idar-Oberstein, Germany,

The first participants in Pfizer and BioNTech’s Phase 1/2 clinical trial for the BNT162 vaccine program have already been dosed in Germany and the U.S.

“The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies …